Company ProfilePremium

Biotoxtech Co., Ltd.

Company Profile Analysis

Ticker: 086040.KQ주식회사 바이오톡스텍

ESOMAR 23 Corporate BadgeISO Certifications Badge
Biotoxtech Co., Ltd. - Company showcase

Year Founded & Workforce

2000

225 Employees

Biotoxtech Co., Ltd. logo

Biotoxtech Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Biotoxtech Co., Ltd. Overview

Biotoxtech is a Korean preclinical contract research organisation (CRO). It generates the GLP safety and efficacy data that drug, chemical, cosmetic, food and agrochemical developers must submit to regulators before human testing or market approval. Founded in 2000 by veterinary toxicologist Kang Jong-koo, it describes itself as Korea's largest private toxicology testing house. It was the first Korean private nonclinical lab to pass a US FDA GLP inspection (January 2015). It is a single-segment business with two operating platforms:

  • The parent company runs rodent and non-rodent toxicology, safety pharmacology, genotoxicity, ecotoxicology and bioanalysis from its Ochang campus.

  • The subsidiary KPrime Research runs a large private non-human primate (NHP) facility at Osong, built in 2022.

After two years of heavy losses (FY2023–FY2024), the group is in a backlog-led recovery. H1 2026 consolidated revenue rose 26% and the subsidiary posted its first quarterly operating profit. However, leverage, negative working capital and a minority-interest deficit at the subsidiary remain the central investment risks.


What the company does. Biotoxtech sells contract nonclinical studies. A sponsor (a pharmaceutical company, biotech, chemical producer or cosmetics/food firm) commissions a study protocol. Biotoxtech conducts the in-life phase in laboratory animals or in vitro systems, analyses samples, and delivers a GLP-compliant final report. The report then goes into regulatory dossiers such as an IND, NDA/BLA, chemical registration or functional-ingredient approval.

Data vendors summarise the company's business as follows:

  • Safety evaluation of medical products, cosmetics, food and chemicals.

  • Efficacy testing and material screening.

  • Consulting on nonclinical test strategy.

The safety-evaluation catalogue spans:

  • General toxicity, carcinogenicity and local toxicity

  • Reproductive/developmental toxicity, genotoxicity and immunotoxicity

  • Safety pharmacology

  • Aquatic ecotoxicology

  • Histopathology/clinical pathology

  • Alternative (non-animal) test methods

Company's own description (paraphrased from company materials). The company presents itself as holding the largest number of GLP-certified test categories and the most completed GLP studies among Korean nonclinical CROs. It cites hundreds of data submissions to US, Japanese and European regulators on behalf of domestic and overseas clients. It highlights:

  • The 2015 FDA GLP inspection.

  • Its selection as Korea's representative CRO for the November 2010 OECD Mutual Joint Visit GLP inspection.

  • Full AAALAC International accreditation, including being the first private Asian CRO accredited for aquatic (environmental) toxicity.

  • Being first in Korea to be certified for safety pharmacology and for alternative animal-test methods.

It also describes:

  • A bioanalysis joint venture (SBB) formed with Japan's Sumika Chemical Analysis Service, to cover small-molecule, antibody and biologic sample analysis.

  • A leading role in chemical risk and aquatic-toxicity assessment under K-REACH (화평법), Korea's chemical registration law.

Revenue model. Revenue comes from fee-for-service study contracts, often milestone-billed and recognised over the study period. Order intake therefore converts to revenue with a lag of several quarters. Management states this explicitly when discussing its backlog. There is no subscription or licensing revenue of note.

Two non-core income streams appear in the financials:

Investment gains: gains on strategic equity stakes, notably in G2GBIO, contributed KRW 8.0bn of FY2025 pre-tax income.

Laboratory-animal sales: the group lists animal sales within its "total service" offer.

Value-chain position. Biotoxtech sits between drug discovery and Phase 1 clinical trials (the "IND-enabling" stage). It also serves the regulatory-safety requirements of chemicals and consumer products. Its value proposition rests on three things:

Regulatory acceptability: OECD GLP mutual acceptance and FDA inspection history.

Species breadth: rodents, non-rodents, and NHPs via KPrime.

Data packaging: it now offers turn-key packages that include SEND datasets, the FDA's standard electronic format for nonclinical data, needed for FDA filings.

Customer types and end markets.

  1. Korean biotech and pharmaceutical companies developing new drugs, biologics, cell and gene therapies, ADCs, ASOs, peptides and vaccines. This is the core base and the source of cyclicality.

  2. Overseas biotechs: historically Japan-centric, now diversifying towards the US, Europe and Singapore (Sep 2026 company statement).

  3. Chemical companies needing K-REACH registration data.

  4. Cosmetics, health-functional-food and agrochemical developers.

  5. Government and public R&D programmes. TheVC registry data lists 29 national R&D projects and 52 B2G contracts.

Independent characterisation. Biotoxtech is a sub-scale but credentialed national champion in a market dominated globally by Charles River, Labcorp, Inotiv and the large Chinese CROs. Domestically its main rival for regulatory-grade toxicology is the government-funded Korea Institute of Toxicology (KIT).

Its economics are those of a high-fixed-cost laboratory operator:

  • Gross margin swings violently with utilisation, from 33% in FY2022 to 6% in FY2023.

  • The 2022 NHP build-out roughly doubled the asset base and loaded the group with debt just as Korean biotech funding contracted.

  • The recovery thesis depends on two things: filling the NHP capacity with export-oriented, higher-value biologics work, and converting a record backlog into utilisation.

Strategy

Stated strategic themes (paraphrased from the Feb 2026 "Letter to Shareholders" and 2026 IR communications).

  1. 2026 as the first year of the earnings turnaround. Management says it completed a structural overhaul through quality improvement and efficiency during the FY2023–FY2024 downturn.

  2. Become a global top-tier nonclinical CRO. Leverage FDA GLP inspection history to win US and European biotech work.

  3. Full-lifecycle nonclinical "total service." Cover primates, rodents and non-rodents, toxicology and efficacy, bioanalysis and laboratory-animal supply under one group.

  4. Move up the value curve into advanced modalities. Build capability in ADC, ASO, peptides, next-generation vaccines and gene therapy, which the company says carry higher average order values and margins.

  5. Package and long-duration contracts. Shift from single studies to turn-key multi-study packages with SEND data and multi-year projects. Management says average order size has moved from a few hundred million won to the KRW 1bn+ range.

  6. Shareholder-value programme. Buybacks (including cancellation), expanded NDR/IR activity and transparent disclosure.

  7. Unlock KPrime's value through an IPO. KPrime has applied for a designated auditor as a formal pre-IPO step.

Strategic initiatives, last 24 months.

Medium-term targets and guidance.

No formal multi-year revenue or margin targets were identified.

ESG/sustainability commitments: no quantified commitments identified. Animal-welfare (AAALAC) and alternative-method (3Rs) activities are the substantive ESG-relevant programmes.

Products & Services

All offerings sit within the single nonclinical CRO segment. Pricing is per study and quoted individually; no list prices are disclosed. Launch years are given only where disclosed.

Parent company (Ochang) — safety evaluation

Service lineDescription and capabilitiesTarget customerNotes
General toxicity (single and repeated dose)Acute to chronic dosing studies in rodents and non-rodents to define target organs and NOAELDrug, biologic, chemical and cosmetic developersCore GLP offering
CarcinogenicityLong-term rodent bioassaysSmall-molecule and chemical sponsorsLong-duration, high-backlog studies
Local toxicityDermal/ocular irritation, sensitisation, injection-site toleranceCosmetics, topical and injectable developersIncludes alternative in-vitro methods
Reproductive & developmental toxicityFertility, embryo-fetal development, pre/postnatal studiesPharma, agrochemical—
GenotoxicityAmes, chromosomal aberration, micronucleus and related assaysAll new-substance sponsorsPart of SEND-ready packages
ImmunotoxicityImmune-function and immunogenicity assessmentBiologics, vaccines—
Safety pharmacologyCNS, respiratory, cardiovascular core batteryPharma/biotechCompany claims the first Korean certification in this field
Aquatic ecotoxicologyFish, daphnia and algae tests for environmental riskChemical companies (K-REACH)AAALAC-accredited aquatic programme (first private Asian CRO)
Histopathology / clinical pathologyTissue evaluation, haematology, clinical chemistryAll study typesIn-house pathology
Alternative animal-test methods (NAMs)Validated in-vitro / non-animal methodsCosmetics (animal-test restrictions), chemicalsCompany claims the first Korean certification; KPrime has a dedicated NAMs task force
Chemical risk assessmentHazard and risk dossiers for K-REACH registrationChemical manufacturers/importersCompany cites hundreds of assessments per year

Parent company — efficacy, analytics and data services

Service lineDescriptionTarget customer
Efficacy evaluationDisease-model pharmacology studies (pipeline partners include obesity, diabetes, dementia, prostate cancer and hair-loss programmes under the G2GBIO agreement)Biotech
Toxicokinetics / pharmacokinetics and bioanalysisSample analysis for small molecules, antibodies and biologics; historically via the SBB JV with Sumika Chemical Analysis ServicePharma/biotech
Material screening & consultingEarly candidate screening and nonclinical strategy designEarly-stage biotech
SEND dataset preparationCDISC-SEND electronic datasets required for FDA submissions, bundled with general toxicity, safety pharmacology, genotoxicity, TK and bioanalysis as a turn-key packageUS-bound sponsors
Turn-key IND packagesMulti-study bundles for advanced modalities (ADC, ASO, peptides, next-generation vaccines, gene therapy)Global biotech; company targets larger, multi-year package contracts

KPrime Research (Osong) — NHP platform

Service lineDescriptionLaunch / certificationTarget customer
NHP repeated-dose toxicity (GLP)Primate toxicology for biologics, ADCs and oligonucleotides where rodents are not pharmacologically relevantGLP certified 2023Global and Korean biotech
NHP cardiovascular safety pharmacology (GLP)Telemetry-based cardiovascular safety studiesGLP certified 2025; described as Korea's first primate safety-pharmacology GLPIND-stage sponsors
Liver and heart biopsy servicesSerial biopsy sampling in primates—Gene/cell therapy, metabolic programmes
Ophthalmic special administrationIntravitreal and other ocular dosing—Ophthalmology drug developers
Immunoassay servicesImmunogenicity and biomarker analysis—Biologics
NHP efficacy & PK studiesNeurodegenerative and other disease models, e.g. the 2022 BioOrchestra MOU2022 onwardRNA/CNS developers

Flagship offerings, by management emphasis:

  • FDA-inspected GLP general toxicity with SEND.

  • NHP GLP toxicology and safety pharmacology at KPrime.

  • Turn-key packages for ADC, ASO and gene-therapy programmes.

Financial Narrative

Source: S&P Global Market Intelligence via StockAnalysis.com, consolidated IFRS, KRW millions, FY ending 31 December. TTM = 12 months to 30 Jun 2026.

Margins and growth

Revenue CAGR FY2021–FY2025: 9.5% (analyst calculation: 47,017 / 32,717 over four years).

TTM to June 2026: revenue KRW 52,476M (+20.9%), gross margin 14.07%, operating margin −8.81%, EBITDA roughly breakeven (KRW −159M), attributable net loss KRW −3,995M.

Commentary.

The FY2023 inflection: FY2023 revenue fell 12.5% while cost of revenue rose 23.8%. Gross margin collapsed from 33% to 6%. Three forces converged:

  • The Korean biotech funding drought hit order intake; management later blamed reduced private and government R&D investment.

  • The new KPrime facility began depreciating and staffing up before revenue arrived.

  • Inventory, mostly laboratory animals and NHPs, built from KRW 4.5bn to KRW 11.9bn ahead of demand.

FY2024: Revenue recovered 26.7%, but cost of revenue grew almost as fast. Operating losses persisted at KRW 8.6bn, and a KRW 3.8bn tax charge (likely deferred-tax-asset write-down; DTA fell from KRW 5.3bn to KRW 1.9bn) deepened the net loss.

FY2025: Gross margin doubled to 12.3% and operating loss narrowed by 31%. Attributable net income turned positive (KRW 1.2bn) only because of an KRW 8.0bn gain on investment sales, most plausibly linked to the G2GBIO stake or other securities. Without that gain, the pre-tax loss would have been about KRW 8.4bn ("EBT excluding unusual items" was KRW −8,371M).

Interest burden: Interest expense rose 6.5x from FY2021 to FY2025, reaching 11.5% of revenue. This is now the single largest drag below EBIT.

SG&A: has been flat at about KRW 8.8bn for three years. Operating leverage on revenue growth should therefore be high.

Balance sheet

30 June 2026 snapshot:

  • Cash and short-term investments KRW 29.3bn.

  • Total debt KRW 68.4bn; net debt KRW 39.1bn.

  • Current liabilities KRW 97.0bn against current assets KRW 52.5bn (working capital KRW −44.4bn).

  • Total equity KRW 22.4bn, of which parent KRW 32.5bn and NCI KRW −10.1bn.

  • Debt/equity 3.05x.

Commentary. The FY2022 balance-sheet step-change reflects KPrime's Osong campus, which doubled PP&E (buildings rose from KRW 22.7bn to KRW 51.2bn). It was funded largely with debt and mezzanine instruments: net debt moved from a KRW 1.1bn net cash position to KRW 18.4bn.

Two features stand out:

Liquidity is structurally tight: IB Tomato (Jan 2026) noted the parent's standalone current ratio exceeds 100%. Consolidating KPrime's short-term borrowings and CBs cuts the ratio by about 45.6 percentage points, to around 60%. KPrime's own cash is insufficient to service its debts, so the parent is the de facto backstop.

"Other current liabilities" are large: KRW 32.9bn at FY2025 and KRW 36.9bn at June 2026. This line likely contains contract liabilities (customer advances on studies) and/or KPrime's CBs. Advances would be a sign of backlog strength rather than financial debt. The split is not publicly disclosed in sources reviewed.

Cash flow

TTM to June 2026: OCF KRW 5.5bn, capex KRW 3.6bn, FCF KRW 1.9bn. Debt issued KRW 14.4bn and repaid KRW 13.8bn (refinancing).

Commentary. Cumulative FCF over FY2021–FY2024 was about KRW −65bn, funded by roughly KRW 76bn of net new debt over FY2021–FY2023. FY2025 was the first year of positive FCF (KRW 4.5bn). Most of the improvement came from working-capital release: inventory fell by KRW 7.5bn as NHP stock was consumed in studies. This is not repeatable at the same scale. The capex cycle is over; maintenance capex is running at about KRW 2–4bn per year. Self-funded deleveraging is therefore possible only once EBITDA turns sustainably positive.

Ratios

Sources: ROE, ROA, ROIC, current/quick ratios, D/E, net debt/equity and asset turnover are from S&P / StockAnalysis. Interest coverage and the working-capital day metrics are analyst calculations from the reported figures. The cash conversion cycle excludes customer advances held in other current liabilities, so the true cash cycle is likely shorter.

Net debt/EBITDA: −0.17x (FY2021) and 6.69x (FY2022). Not meaningful for FY2023–FY2025 because EBITDA was negative. Current June 2026 D/E: 3.05x.

Ratio commentary. All return metrics have been negative since FY2023. Interest coverage has been below 1x since FY2022. The cash conversion cycle peaked above 200 days in FY2024, driven by animal inventory, and has since normalised. The current ratio has deteriorated every year since FY2023; refinancing of short-term bank lines and CBs is therefore the core financial risk.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRoleLocationOwnership

Biotoxtech Co., Ltd. (parent)

Rodent/non-rodent toxicology, safety pharmacology, genotoxicity, ecotoxicology, efficacy, bioanalysis, chemical risk assessment

Ochang, Cheongju

Listed

KPrime Research Co., Ltd. (키프라임리서치)

NHP toxicology, safety pharmacology (cardiovascular telemetry), biopsy services, ophthalmic dosing, immunoassays

Osong, Cheongju

Consolidated subsidiary. Exact stake not publicly disclosed in sources reviewed; a large minority interest exists (see below)

SBB (JV with Sumika Chemical Analysis Service)

Bioanalysis (TK/PK)

Korea (location not disclosed)

A FY2022 divestiture/discontinued-operation entry may relate to a disposed affiliate (unconfirmed)

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Nonclinical CRO revenue (KRW Mn)

32,71737,29232,63141,34147,017

Nonclinical CRO revenue YoY growth (%)

23.7913.98-12.5026.6913.73

Nonclinical CRO operating income (KRW Mn)

4,632800-8,676-8,619-5,908

Nonclinical CRO operating margin (%)

14.162.15-26.59-20.85-12.57

Share of total revenue (%)

100100100100100

Revenue by Segment (KRW) and Segment Margins & Growth (%)

MetricH1 2025H1 2026

Consolidated revenue (KRW 100M)

208263

Consolidated operating income (KRW 100M)

-33-20

Parent standalone revenue (KRW 100M, H1 2025 derived from +8% growth)

149161

Parent standalone new orders (KRW 100M, H1 2025 derived from +17% growth)

169198

Parent standalone order backlog at period end (KRW 100M, H1 2025 derived from +18% growth)

369435

Kprime Metric Details

KPrime metricValuePeriod / source

Q2 2026 revenue

KRW 5.8bn

BizWatch, 19 Aug 2026

Q2 2026 operating income

KRW 0.4bn (first quarterly profit since founding)

BizWatch, 19 Aug 2026

H1 2026 new contracts

KRW 17.2bn, of which >60% from overseas clients

BizWatch / Asia Economy, Aug 2026

Implied H1 2026 revenue

~KRW 10.2bn (consolidated KRW 26.3bn less parent KRW 16.1bn, before intercompany eliminations)

Analyst derivation

Implied FY2025 revenue

~KRW 14–14.5bn. Derived from the Feb 2026 USD 2.45M contract (>25% of prior-year revenue) and the Mar 2026 €1.38M contract (16.5% of prior-year revenue)

Analyst derivation

Combined group backlog at end-June 2026

KRW 60.7bn (parent KRW 43.5bn + KPrime ~KRW 17.2bn by subtraction)

BizWatch, 19 Aug 2026

Growth track record

Orders and revenue grew >100% per year since operations began in 2023

Company letter, Feb 2026

Revenue from US/Europe

~50% (FY2025)

Company letter, Feb 2026

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Mn)

32,71737,29232,63141,34147,017

Cost of revenue (KRW Mn)

22,20824,86330,76938,84241,215

Gross profit (KRW Mn)

10,50912,4291,8622,4995,802

SG&A (KRW Mn)

5,3629,3198,7738,8108,765

Operating income (KRW Mn)

4,632800-8,676-8,619-5,908

D&A (KRW Mn)

1,6721,9453,6794,0984,333

EBITDA (KRW Mn)

6,3042,745-4,998-4,521-1,576

Interest expense (KRW Mn)

8332,0153,7645,0865,425

Gain on sale of investments (KRW Mn)

1,8461,47213-1,2428,030

Pre-tax income (KRW Mn)

6,485-644-11,833-8,822-346

Income tax expense (KRW Mn)

-213-709-2,8833,8361,228

Net income to company incl. minorities (KRW Mn)

6,9801,512-8,950-12,657-1,573

Minority interest share of losses (KRW Mn)

1341,2144,0736,2302,736

Net income attributable to parent (KRW Mn)

7,1142,725-4,878-6,4271,163

EPS basic (KRW)

486.65186.19-316.14-405.0074.43

EPS diluted (KRW)

444.28185.86-316.14-405.0074.43

Dividends per share (KRW)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth (%)

23.7913.98-12.5026.6913.73

Gross margin (%)

32.1233.335.716.0412.34

Operating margin (%)

14.162.15-26.59-20.85-12.57

EBITDA margin (%)

19.277.36-15.32-10.94-3.35

Net margin, attributable (%)

21.747.31-14.95-15.552.47

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Mn)

90,741125,700147,036136,191131,607

Cash & equivalents (KRW Mn)

18,59212,70027,47911,37018,632

Cash + short-term investments (KRW Mn)

28,15130,77141,03832,38428,132

Accounts receivable (KRW Mn)

5,8137,3525,3557,8638,700

Inventory (KRW Mn)

6744,45411,91514,7867,218

Property, plant & equipment (KRW Mn)

25,40958,06658,18156,51655,071

Long-term investments (KRW Mn)

18,37310,13010,68910,32018,902

Goodwill & intangibles (KRW Mn)

1,4791,4831,5961,6651,276

Short-term debt incl. current portion of LTD (KRW Mn)

24,84328,85341,22946,56851,037

Long-term debt (KRW Mn)

1,90920,00020,00016,25011,250

Total debt incl. leases (KRW Mn)

27,04949,14061,59163,04962,500

Net debt (KRW Mn)

-1,10218,36920,55330,66534,367

Total current assets (KRW Mn)

37,74649,13064,69258,91848,615

Total current liabilities (KRW Mn)

45,77759,52875,11982,21085,492

Working capital (KRW Mn)

-8,031-10,398-10,426-23,292-36,877

Parent shareholders' equity (KRW Mn)

41,14444,23551,71040,08240,157

Non-controlling interest (KRW Mn)

706132-3,475-5,557-8,226

Total equity (KRW Mn)

41,84944,36748,23534,52531,931

Treasury stock (KRW Mn)

-166-166-166-1,163-2,161

Book value per share (KRW)

2,8113,0223,2472,5502,607

Cash Flow and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Mn)

4,346-1,309-16,238-7,1206,636

Capital expenditure (KRW Mn)

-7,619-30,676-4,452-1,977-2,121

Free cash flow (KRW Mn)

-3,273-31,985-20,691-9,0974,515

Capex as % of revenue (%)

23.382.313.64.84.5

Dividends paid (KRW Mn)

00000

Share buybacks (KRW Mn)

000-997-998

Net debt issued / repaid (KRW Mn)

19,06621,93432,8061,987-4,491

Investing cash flow (KRW Mn)

-7,757-26,399-1,978-9,8416,183

Financing cash flow (KRW Mn)

19,27921,92933,022762-5,489

Cash interest paid (KRW Mn)

4138361,8512,0161,661

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

Return on equity (%)

17.590.15-19.33-30.59-4.74

Return on assets (%)

3.750.46-3.98-3.80-2.76

Return on invested capital (%)

13.031.55-13.19-12.87-8.99

Current ratio (x)

0.830.830.860.720.57

Quick ratio (x)

0.770.640.620.500.44

Debt to equity (x)

0.651.111.281.831.96

Net debt to equity (x)

-0.030.410.430.891.08

Interest coverage, EBIT/interest (x)

5.560.40-2.30-1.69-1.09

Asset turnover (x)

0.420.350.240.290.35

Days sales outstanding (days)

64.972.059.969.467.5

Days inventory outstanding (days)

11.165.4141.3138.963.9

Days payables outstanding (days)

13.411.56.46.36.1

Cash conversion cycle (days)

62.6125.9194.8202.0125.3

Geographic Revenue

IndicatorValuePeriodSource

KPrime revenue from US & Europe

~50%

FY2025

Company letter, Feb 2026

KPrime new contracts from overseas clients

60% of KRW 17.2bn

H1 2026

BizWatch, Aug 2026

KPrime 2026 target: overseas share of orders

50% of KRW 30bn+ target

FY2026 target

KPrime CEO Kim Dong-il, Feb 2026

Parent US/EU nonclinical order intake

Expected ~3x FY2025 (+200%)

FY2026 guidance

Company, Sep 2026

Parent overseas client base

Historically Japan-led; now diversifying to US, Europe, Singapore

2026

Company, Sep 2026

Regulatory submissions using group data

25 (18 overseas INDs, 7 NDA/BLA)

2023 – Sep 2026

Company, Sep 2026

Share Price and Market Valuation

MetricFY2021FY2022FY2023FY2024FY2025

Year-end share price (KRW)

8,0208,1406,1603,3352,815

Market capitalisation (KRW Mn)

117,384119,14098,11352,42944,254

Enterprise value (KRW Mn)

118,446128,169127,34278,21275,280

Price / sales (x)

3.593.203.011.270.94

Price / book (x)

2.812.692.031.521.39

EV / sales (x)

3.623.443.901.891.60

Market cap growth (%)

-47.091.50-17.65-46.56-15.59

Share Price & Returns

WindowReturnBasis

Year-to-date (from KRW 2,815 at FY2025 close)

≈ −26%

Analyst calculation

Since FY2023 close (KRW 6,160), ≈2.8 years

≈ −66%

Analyst calculation; proxy for 3-year

Since FY2021 close (KRW 8,020), ≈4.8 years

≈ −74%

Analyst calculation; proxy for 5-year

52-week range

KRW 1,896 – 4,115

Investing.com / StockHub

Capital Markets

ItemDetail

Dividend history

No dividends paid FY2021–FY2025; none currently (Stockopedia)

Buybacks

~KRW 997M (FY2024); ~KRW 998M (FY2025, trust 27 Aug 2025 – 26 Feb 2026)

Policy

Management has stated intent to pursue buybacks including cancellation (Feb 2026)

Treasury ratio

~3.46%

Capital Markets — Short-term borrowings

ItemKRW MnNotes

Short-term borrowings

53,493

Bank lines; refinanced on a rolling basis (TTM issued KRW 14.4bn / repaid KRW 13.8bn)

Current portion of long-term debt

5,000

Due within 12 months

Long-term debt

9,550

Maturities not disclosed

Leases

316

Current KRW 192M + long-term KRW 124M

Total debt

68,359—

Cash and short-term investments

29,255

Includes KRW 4.4bn of trading securities

Analyst Conclusions

Management guidance (qualitative):

  • FY2026 is the turnaround year.

  • Parent standalone operating profit in H2 2026 is described as highly likely.

  • KPrime operating profit is expected to widen from Q3 2026, with a full-year profit described as likely.

  • KPrime targets FY2026 order intake above KRW 30bn, with more than half from overseas.

  • US/EU orders at the parent are guided at about 3x FY2025.

Consensus: no active sell-side consensus.

Implied run-rate. H1 2026 revenue of KRW 26.3bn, plus backlog conversion, suggests FY2026 revenue in the mid-KRW 50bn range. This is analyst extrapolation, not guidance.

Bull case

  1. Backlog converts with operating leverage. Group backlog of KRW 60.7bn exceeds a year of revenue, and SG&A is flat at ~KRW 8.8bn. Every KRW 10bn of added revenue at a mid-20s gross margin would add roughly KRW 2.5bn to EBIT, which would push the group to operating breakeven or better in FY2027.

  2. KPrime becomes a profitable export franchise. It posted its first operating profit in Q2 2026, over 60% of H1 contracts were overseas, and primate capacity is scarce globally. A successful KOSDAQ IPO could recapitalise the subsidiary, eliminate the negative NCI and revalue the parent's stake well above the current KRW 32.7bn group market cap.

  3. Modality mix lifts margins. The pivot to ADC/ASO/gene-therapy studies and turn-key SEND packages raises contract size and margins. Rising US/EU audit activity points to further export wins.

Bear case

  1. Balance sheet outruns the recovery. Current liabilities of KRW 97bn against current assets of KRW 52.5bn, D/E of 3.05x and interest of about KRW 5.4bn per year leave little margin for error. Successive CB refinancings risk serial dilution at depressed prices.

  2. Parent business remains structurally weak. Standalone revenue grew only 8% in H1 2026 in a domestic market marked by low-price competition and client credit stress. FY2025 profitability relied on one-off investment gains.

  3. Turnaround has been announced before. The share price has fallen about 74% since the FY2021 close despite repeated recovery messaging. Investment-gain volatility (G2GBIO) and minority-interest accounting obscure underlying earnings. A slip in the Q3/Q4 2026 profit milestones would test credibility further.

Key catalysts and monitorables (next 12 months)

  1. Q3 2026 results (mid-Nov 2026): parent standalone operating profit; KPrime margin progression.

  2. Terms of the August 2026 CB (size, conversion price, refixing floor, put options) and the related large-shareholding filing.

  3. KPrime IPO timeline: preliminary review filing with the Korea Exchange.

  4. FY2026 order intake versus the KPrime KRW 30bn target and the parent's US/EU 3x guidance.

  5. Short-term debt rollover and any equity raise.

  6. G2GBIO stake valuation and any realisation.

  7. Celltrion's holding: any change to the ~10.22% stake.

  8. Any new FDA/OECD inspection outcome or GLP certification extension.

Analyst verdict

Biotoxtech is a credentialed but financially strained national toxicology champion in the middle of an operational turnaround. The operating evidence of 2026 is real:

  • H1 consolidated revenue rose 26%.

  • The operating loss narrowed by about 40%.

  • KPrime reached its first quarterly profit.

  • Group backlog stands at a record KRW 60.7bn.

  • The client base is shifting decisively towards US and European biotechs working on advanced modalities, where Korea-based NHP capacity and FDA-inspected GLP data are genuinely differentiated.

The asset base is largely in place after the KRW 30bn-plus 2022 build-out. With SG&A flat for three years, incremental revenue should carry high drop-through.

The equity story, however, is dominated by the capital structure rather than the operations:

  • Consolidated debt of KRW 68bn sits against roughly KRW 22bn of total equity.

  • Working capital is deeply negative.

  • A subsidiary with KRW 27.5bn of CBs depends on parent support.

  • The 2021 CB has just matured into a new CB issue.

The FY2025 return to attributable profit was an artefact of investment gains, and the TTM attributable result has slipped back to a KRW 4.0bn loss. Equity holders therefore face a race between EBITDA recovery and dilutive refinancing.

At about 0.6x sales and roughly 1x tangible book, the market is pricing a high probability that the race is lost or that value accrues mainly to mezzanine and KPrime minority holders. The upside case requires three things in sequence:

  1. Sustained positive EBITDA from H2 2026.

  2. A KPrime IPO that recapitalises the subsidiary on terms accretive to the parent.

  3. No further deep-discount CB issuance.

Overall assessment: speculative recovery situation. The operating thesis is improving but the balance-sheet risk is high. The Q3 2026 standalone profitability print and the August 2026 CB terms are the two data points that should determine conviction. Investors and counterparties should complete diligence on the DART annual report (risk factors, related-party transactions, KPrime ownership) before relying on this assessment.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation

Kang Jong-koo (강종구)

Chairman & CEO (대표이사 회장), Biotoxtech; Chairman of KPrime Research

Founder, since 2000

BVM and MS, Seoul National University; PhD, University of Tokyo graduate school. Formerly at a Japanese safety-evaluation research institute (named "Hypox" in Korean transliteration in the IR deck). Professor, College of Veterinary Medicine, Chungbuk National University (as of 2018)

Not publicly disclosed. Korean rules require individual disclosure only above KRW 500M

Lee Byung-kyu (이병규)

Co-CEO at IPO (2007)

———

Kim Dong-il (김동일)

CEO, KPrime Research

Since at least 2022

——

“—” = not publicly disclosed.

Board & Management Changes

DateEvent

Early 2026

First round of on-market share purchases by senior executives

Aug 2026

Second "relay" round: CEO Kang bought the same number of shares as each participating executive, framed as accountability and confidence in recovery (Money Today, 10 Aug 2026)

26 Aug 2026

Filing of an executive/major-shareholder specific-securities ownership report and a large-shareholding (5%+) report.

Major Shareholders

HolderStakeDateSource

Kang Jong-koo and related parties

15.96% (2,324,616 shares)

30 Apr 2018

2018 IR deck

Kang Jong-koo (individual)

13.98%

H1 2018

Dailypharm, Oct 2018

Celltrion Inc.

11.20% (1,631,134 shares)

30 Apr 2018

2018 IR deck

Celltrion Inc.

~10.22%

Feb 2026

Company letter via BizWatch / Herald

Treasury shares

~3.46%

2026

Butler.works

Other / free float

Remainder

——

Competitive Landscape

Key Competitors

CompetitorType / domicileOverlap with BiotoxtechRelative positioning

Korea Institute of Toxicology (KIT, 안전성평가연구소)

Government-funded research institute, Korea

GLP toxicology including NHP

Largest domestic public-sector rival; subsidised capacity

Dt&CRO (디티앤씨알오, KOSDAQ 383930)

Listed CRO, Korea

Efficacy and GLP toxicology; nonclinical-to-Phase-1 full service

Differentiates on full service from nonclinical through Phase 1; revenue mix shifting towards clinical

Chemon (켐온)

Private / Korea

GLP toxicology

Direct domestic toxicology rival

Kolmar BioTech (formerly Woojung Bio)

Listed, Korea

Nonclinical efficacy CRO; pivoting to cosmetics safety CRO

Loss-making peer (H1 2025: revenue KRW 15.4bn, operating loss KRW 3.0bn)

Knotus (노터스)

Korea

Efficacy studies

Niche efficacy competitor

Charles River Laboratories

Global, US

Full nonclinical including NHP

—

Labcorp (early development)

Global, US

Nonclinical toxicology

Global major

Inotiv

US

Nonclinical toxicology, research models

Mid-size US competitor

WuXi AppTec / Pharmaron / JOINN Laboratories

China

Nonclinical toxicology including NHP

Price-competitive Asian rivals with large primate capacity

Shin Nippon Biomedical Laboratories (SNBL)

Japan

NHP toxicology

Competes for Japanese and global primate work

Peer Comparison FY2025

MetricBiotoxtech (FY2025)Biotoxtech (H1 2026)Kolmar BioTech / Woojung Bio (H1 2025)

Revenue

KRW 47.0bn

KRW 26.3bn

KRW 15.4bn

Revenue growth

+13.7%+26%—

Operating margin

−12.6%

~−7.6%

~−19.6%

R&D intensity

1.4%——

“—” = not publicly disclosed.

Recent Developments

All identifiable material items are listed; dates are publication or filing dates.

Not identified in the period: * litigation, regulatory sanctions, layoffs, guidance withdrawals or CEO changes.

Company Snapshot

$33.1M

Revenue

225

Employees

2000

Founded

Cheongju, South Korea

Headquarters

SWOT Analysis

Strengths

  • Regulatory credentials: first Korean private nonclinical facility to pass an FDA GLP inspection (Jan 2015); Korea's representative CRO for the Nov 2010 OECD MJV inspection.
  • Proven global data acceptance: 25 global regulatory uses of its data since 2023 (18 INDs, 7 NDA/BLA), per the company in Sep 2026.
  • NHP platform: KPrime's Osong facility of ~1,150 heads, the largest private primate facility in Korea. GLP for repeated-dose (2023) and cardiovascular safety pharmacology (2025).
  • Backlog visibility: group backlog of KRW 60.7bn at June 2026, about 1.16x TTM revenue of KRW 52.5bn. Parent backlog grew 18% year on year.
  • Export traction: over 60% of KPrime's H1 2026 new contracts came from overseas; largest-ever contracts in Feb–Mar 2026 (USD 2.45M; €1.38M).
  • Strategic shareholder: Celltrion holds ~10.22% (Feb 2026).

Weaknesses

  • Persistent operating losses: FY2023 −KRW 8.7bn, FY2024 −KRW 8.6bn, FY2025 −KRW 5.9bn; operating margin still −8.8% on a TTM basis.
  • Leverage: total debt of KRW 68.4bn vs. total equity of KRW 22.4bn (D/E 3.05x, June 2026); interest coverage negative since FY2023.
  • Liquidity: current ratio of 0.54x and working capital of KRW −44.4bn (June 2026). IB Tomato reports the current ratio falls ~45.6pp when KPrime is consolidated.
  • Earnings quality: FY2025 attributable profit (KRW 1.2bn) depended on KRW 8.0bn of investment gains; underlying pre-tax loss of ~KRW 8.4bn.
  • Minimal R&D and IP: R&D at 1.4% of revenue (FY2025); 2 patents.
  • Subsidiary capital deficit: non-controlling interest of KRW −10.1bn (June 2026), reflecting cumulative KPrime losses beyond minority capital.

Opportunities

  • KPrime IPO: designated-auditor application (Feb 2026) could crystallise value and recapitalise the subsidiary.
  • Advanced modalities: ADC, ASO and gene-therapy studies carry higher prices and margins, per the company (Sep 2026).
  • US/EU demand: 2026 US/EU orders guided at ~3x 2025; rising audits by large US/EU biotechs in H2 2026.
  • Turn-key packages with SEND: larger contract sizes, with the company citing a shift to KRW 1bn+ projects.
  • Operating leverage: SG&A flat at ~KRW 8.8bn for three years, so incremental gross profit flows largely to EBIT.
  • NAMs leadership: first Korean alternative-method certification and a dedicated NAMs task force position the company for regulatory change.

Threats

  • Refinancing risk: short-term debt of KRW 53.5bn (June 2026) plus subsidiary CBs of KRW 27.5bn; the parent CB matured in Aug 2026, with a new CB filing on 24 Aug 2026.
  • Domestic price war: industry sources cite loss-making competitors bidding low and biotech clients defaulting on receivables (Aug 2025).
  • Dilution / overhang: multiple CB and BW instruments (KRW 18bn CB in 2021; KRW 12bn BW in 2024; new 2026 CB; KPrime CBs). Share count rose ~8.8% in FY2023.
  • Regulatory shift away from animal testing: reduced study volumes over the long term.
  • NHP supply and cost volatility: inventory swung from KRW 0.7bn (FY2021) to KRW 14.8bn (FY2024).
  • Investment-gain volatility: the G2GBIO stake appears to have been marked from ~KRW 13bn (Mar 2026) to ~KRW 4.4bn of trading securities (June 2026), an analyst inference.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
H1 2025Consolidated H1 2025 revenue KRW 20.8bn; operating loss KRW 3.3bnBase period for the 2026 recovery comparison
21 Aug 2025Industry press reports Korean nonclinical CROs still loss-making amid low-price competition and receivables problemsSector context; peer Woojung Bio posted H1 revenue of KRW 15.4bn and an operating loss of KRW 3.0bn
27 Aug 2025KRW 1.0bn treasury-share trust contract begins (to 26 Feb 2026)Capital return despite losses
2025 (date n/d)Exclusive nonclinical services agreement with G2GBIOPipeline-linked demand
2025 (date n/d)KPrime obtains NHP cardiovascular safety-pharmacology GLP certificationExtends the NHP service menu
Q4 2025Second-highest quarterly order intake in company historyLead indicator for FY2026 revenue
31 Dec 2025FY2025: revenue KRW 47.0bn (+13.7%); operating loss KRW 5.9bn; attributable net profit KRW 1.2bn (investment gains); standalone backlog KRW 41.5bnLoss narrowing; first positive FCF since FY2021
23 Jan 2026IB Tomato analysis flags the consolidated liquidity risk from KPrime's short-term debt and KRW 27.5bn of CBsHighlights refinancing risk
19 Feb 2026KPrime wins its largest-ever NHP contract: USD 2.45M (~KRW 3.5bn), US clientUS validation of the NHP platform
23 Feb 2026Letter to shareholders: 2026 is the turnaround year; Celltrion ~10.22%; KPrime IPO steps begunStrategic reset messaging
Early 2026First round of executive share purchasesInsider alignment
17 Mar 2026KPrime signs a €1.38M GLP contract with a European ADC developer; KRW 12bn+ of KPrime orders year-to-date; 300 incoming NHPs fully bookedEU and ADC credentials
19 Mar 2026Company publicises a ~13x paper return on its G2GBIO stake (~KRW 13bn value vs. a KRW 1.0bn cost)Non-core asset value; volatility risk
Mar 2026FY2025 audited annual report filed (date per DART; not directly verified)Statutory
May 2026Q1 2026 quarterly report (figures not separately retrieved)Statutory
10 Aug 2026Second "relay" of executive and CEO share purchases; management cites H1 orders up 20%+ and a shift to KRW 1bn-scale multi-year projectsInsider confidence
14 Aug 2026H1 2026 half-year report filedStatutory
19 Aug 2026H1 2026: consolidated revenue KRW 26.3bn (+26%); operating loss KRW 2.0bn (vs. KRW 3.3bn); KPrime Q2 operating profit KRW 0.4bn on revenue KRW 5.8bn; group backlog KRW 60.7bnTurnaround evidence
19 Aug 2026Parent standalone H1: revenue KRW 16.1bn (+8%); new orders KRW 19.8bn (+17%); backlog KRW 43.5bn (+18%)Parent recovery slower than KPrime's
24 Aug 2026CB issuance decision (major-matters report, attachment added) and securities issuance result filed. Coincides with the maturity of the August 2021 KRW 18bn CB–
26 Aug 2026Large-shareholding report and executive/major-shareholder ownership report filed–
30 Sep 2026Company guides US/EU nonclinical orders ~3x in 2026; discloses 25 global regulatory uses of its data (18 IND, 7 NDA/BLA) since 2023; rising audits by large US/EU biotechsExport momentum; modality upgrade
3–15 Oct 2026Share price drifts to KRW 2,080–2,275, near the 52-week low of KRW 1,896Market scepticism; possible CB overhang
Nov 2026 (expected)Q3 2026 quarterly report due (statutory deadline mid-November)Test of the H2 standalone profit claim

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 32,717 Mn in FY2021 to KRW 47,017 Mn in FY2025.
Biotoxtech Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue32,71737,29232,63141,34147,017
Cost of revenue22,20824,86330,76938,84241,215
Gross profit10,50912,4291,8622,4995,802

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. StockAnalysis.com (S&P Global Market Intelligence data): Biotoxtech financials, income statement, balance sheet, cash flow, ratios (stockanalysis.com)
  2. Butler.works — company summary, FY2021–FY2025 reported results, DART filing index (butler.works)
  3. BizWatch, 19 Aug 2026 — H1 2026 results, KPrime first quarterly profit (news.bizwatch.co.kr)
  4. BizWatch, 23 Feb 2026 — Letter to shareholders, backlog, Celltrion stake, KPrime IPO (news.bizwatch.co.kr)
  5. Herald Economy, Feb 2026 — Turnaround statement (heraldk.com)
  6. Asia Economy CORE, 19 Aug 2026 — H1 2026 results (core.asiae.co.kr)
  7. Asia Economy CORE, 30 Sep 2026 — US/EU orders 3x, 25 regulatory submissions (core.asiae.co.kr)
  8. Asia Economy, Feb 2026 — KPrime USD 2.45M contract, GLP certifications (view.asiae.co.kr)
  9. Asia Economy, Mar 2026 — KPrime €1.38M ADC contract (view.asiae.co.kr)
  10. Asia Economy, Mar 2026 — G2GBIO investment (view.asiae.co.kr)
  11. E-Daily (English), 19 Aug 2026 — H1 2026 (en.edaily.co.kr)
  12. Money Today, 10 Aug 2026 — Executive share purchases (mt.co.kr)
  13. IB Tomato, Jan 2026 — Consolidated liquidity risk, KPrime CBs (newstomato.com)
  14. E-Daily, 2021 — KRW 18bn CB (edaily.co.kr)
  15. Daum Finance — 2024 BW headline (m.finance.daum.net)
  16. Biotoxtech IR deck, Q2 2018 — company overview, listing date, shareholders — 주요 경영현황 및Q&A(국내).pdf (file.alphasquare.co.kr)
  17. eToday, Aug 2007 — IPO press conference (etoday.co.kr)
  18. Money Today, Nov 2009 — CEO interview, facility investment (mt.co.kr)
  19. Dailypharm, Oct 2018 — Celltrion stake (dailypharm.com)
  20. eToday, Aug 2018 — Woojung Bio strategic investment (etoday.co.kr)
  21. Medigate News, May 2022 — KPrime/BioOrchestra MOU, Osong campus (medigatenews.com)
  22. The Fact, Nov 2022 — KPrime Osong campus completion (news.tf.co.kr)
  23. JobPlanet — company profile (certifications, SBB JV) (jobplanet.co.kr)
  24. TheVC — Biotoxtech and KPrime registry data · thevc.kr
  25. BizWatch, Aug 2025 — Korean CRO sector H1 2025 (news.bizwatch.co.kr)
  26. Dailypharm, Nov 2022 — Korean CRO competitive map (dailypharm.com)
  27. Investing.com — price, market cap, employees (investing.com)
  28. Simply Wall St — company profile (simplywall.st)
  29. Morningstar — company profile (morningstar.com.au)
  30. Stockopedia — consensus and dividend status (stockopedia.com)
  31. StockHub — price, 52-week range, buyback trust, coverage (stockhub.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.